Evidence map›Paper›PMID 31813809›Full record

ArticleEuropean urology focus2021

Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.

Renzo G DiNatale, Alexander N Gorelick, Vladimir Makarov, Kyle A Blum, Andrew W Silagy, Benjamin Freeman, Diego Chowell, Julian Marcon, Roy Mano, Alex Sanchez and 12 more

Open access · greenAbstract read
In one paragraph

Article in European urology focus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Guideline
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Molecularly defined renal cell carcinomas.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026
    Review
  7. Review
  8. ELOC-Mutated Renal Cell Carcinoma is a Rare Indolent Tumor With Distinctive Genomic Characteristics.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025
    Article
  9. Review
  10. Article
  11. Frontiers in oncology · 2025
    Article
  12. Article
  13. Genomic alterations and diagnosis of renal cancer.Virchows Archiv : an international journal of pathology · 2024
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

Renzo G DiNataleUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alexander N GorelickComputational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Vladimir MakarovImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kyle A BlumUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew W SilagyUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Benjamin FreemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Diego ChowellImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Julian MarconUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Roy ManoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alex SanchezUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kyrollis AttallaUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Stanley WengUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Martin VossGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Robert J MotzerGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paul RussoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jonathan A ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Victor E ReuterPathology Department, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ying-Bei ChenPathology Department, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Timothy A ChanImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ed ReznikComputational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Satish K TickooPathology Department, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: tickoos@mskcc.org.
A Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hakimia@mskcc.org.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
UROLOGY ONCOLOGY RESEARCH TRAINING GRANTT32CA082088 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Brett Stewart Carver · 1999 to 2026
$7.1M
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA082088
6 · The paper itself

Abstract

backgroundTCEB1-mutant renal cell carcinoma (RCC) is a rare variant of RCC with clear-cell features. Owing to its unique morphological and molecular features it has recently been proposed as a separate entity. Initial series suggested an indolent, early-stage phenotype. Here we expand our clinical cohort and describe a more detailed genomic analysis looking for potential drivers of aggressiveness. DESIGN, SETTING, AND

participantsWe identified five new cases in our institutional sequencing cohort, four of whom were found to have high-stage disease (American Joint Committee on Cancer stage III/IV). Twelve previously reported cases were pooled for comparison purposes (Sato, The Cancer Genome Atlas, TRACERx Renal). OUTCOME MEASURES AND STATISTICAL ANALYSIS: We used our previously validated pipeline to analyze somatic mutations and copy number alterations (CNAs) in seven tumor samples with available data and estimated the number of cancer cells bearing each somatic mutation. The oncogenic potential of mutations was assessed using OncoKB and two other algorithms. Mann-Whitney U tests were used to evaluate differences in genomic markers between stage groups. RESULTS AND LIMITATIONS: All tumors showed biallelic inactivation of the TCEB1 gene according to a combination of somatic mutation and CNA analyses. Mutations were always found in residues involved in hydrophobic interactions with VHL. We found that high-stage tumors had additional oncogenic mutations (median 1, interquartile range [IQR] 1-1 vs 2, IQR 2-2; median difference 1, 95% confidence interval [CI] 1-1; p= 0.002) and showed whole-genome doubling events. They also seemed to have a higher burden of somatic CNAs (median fraction CNA genome 0.10, IQR 0.10-0.15 vs 0.63, IQR 0.58-0.68), however, this finding did not reach statistical significance (median difference 0.49, 95% CI 0.33-0.63; p=0.052).

conclusionsTCEB1-mutant RCC can show variable behavior ranging from very indolent to aggressive. Specific molecular events leading to high genomic instability seem to be associated with aggressiveness. This study expands the clinical spectrum of TCEB1-mutant RCC. PATIENT SUMMARY: We present four cases of aggressive TCEB1-mutant renal cell carcinoma, a rare type of kidney cancer. In-depth analysis of the genomes of these tumors revealed certain abnormalities that might explain this aggressive behavior.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellDNA Copy Number VariationsGenomicsHumansKidney NeoplasmsSequence Analysis, DNABiomarkers, TumorDNA mutational analysisGenomic instabilityMetastasisRenal cell carcinomaTumor suppressor genes

Identifiers

PMID31813809
PMCPMC7274909
OpenAlexW2993588588

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.